Citations

Clear

2416 citation(s) found for "Yu, Jason L".

Effect of Statins on the Clinical Outcomes of Patients with Sepsis
Goodin, Jason E, Manrique, Camila, Dulohery, Megan M., Sampson, Julia , Saettele, Megan R., Dabbagh, Ousama, Sampson, J.

Mayo Clinic

Anaesthesia and Intensive Care | January 22, 2019 | Volume: 39 | Issue: 6 | Pages: 1051-1055

10.1177/0310057x1103900611 | PMID 22165357 Get It

Despite numerous attempts at novel intervention and tests to aid in earlier diagnosis and improved treatment, there has been an increased incidence of overall mortality related to sepsis, despite improvements in in-hospital mortality. Statins have emerged as potential immunomodulatory and antioxidant agents that might impact on sepsis outcomes. Definitive evidence to support the routine use of statins in patients with sepsis has not yet been elicited. We retrospectively analysed data from patients who presented with sepsis, severe sepsis or septic shock, stratifiying them according to statin use into two groups (statin and no statin). Sequential Organ Failure Assessment was used to evaluate severity of illness. The primary outcome was hospital mortality. Secondary outcomes included intensive care unit (ICU) mortality, hospital and ICU length of stay, and mechanical ventilation and vasopressor therapy duration. Five hundred and sixty-eight patients were included. Patients with prior statin use (statin group) were older, more obese and had higher prevalence of smoking, diabetes and ischaemic heart disease. There was no difference in Sequential Organ Failure Assessment scores and mortality did not vary between the two groups (19.6 vs 16.9%). Furthermore, secondary outcomes including ICU mortality, hospital and ICU length of stay, mechanical ventilation and vasopressor duration did not differ. Multivariate analysis revealed age and Sequential Organ Failure Assessment score were independent predictors of survival, while history of statin use was not (P=0.403). This current retrospective study did not find any benefit of statin use on primary and secondary outcomes of the patients admitted to an academic hospital with sepsis.
Procedural predictors of epidural blood patch efficacy in spontaneous intracranial hypotension
Pagani-Estévez, Gabriel L., Cutsforth‐Gregory, Jeremy K. , Mokri, Bahram, Piepgras, David G., Mauck, William D. , Eldrige, Jason S. , Watson, James C. , Morris, Jonathan M.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 13, 2019 | Volume: 44 | Issue: 2 | Pages: 212-220

10.1136/rapm-2018-000021 | PMID 30636714 Get It

Background and objective Epidural blood patch (EBP) is a safe and effective treatment for spontaneous intracranial hypotension (SIH), but clinical and procedural variables that predict EBP efficacy remain nebulous. Methods This study is an institutional review board-approved retrospective case series with dichotomized EBP efficacy defined at 3 months. The study included 202 patients receiving 604 EBPs; iatrogenic cerebrospinal fluid leaks were excluded. Results Of the EBPs, 473 (78%) were single-level, 349 (58%) lumbar, 75 (12%) bilevel, and 56 (9%) multilevel (≥3 levels). Higher volume (OR 1.64; p<0.0001), bilevel (3.17, 1.91–5.27; p<0.0001), and multilevel (117.3, 28.04–490.67; p<0.0001) EBP strategies predicted greater efficacy. Only volume (1.64, 1.47–1.87; p<0.0001) remained significant in multivariate analysis. Site-directed patches were more effective than non-targeted patches (8.35, 0.97–72.1; p=0.033). Lower thoracic plus lumbar was the most successful bilevel strategy, lasting for a median of 74 (3–187) days. Conclusions In this large cohort of EBP in SIH, volume, number of spinal levels injected, and site-directed strategies significantly correlated with greater likelihood of first EBP efficacy. Volume and leak site coverage likely explain the increased efficacy with bilevel and multilevel patches. In patients with cryptogenic leak site, and either moderate disability, negative prognostic brain MRI findings for successful EBP, or failed previous lumbar EBP, a low thoracic plus lumbar bilevel EBP strategy is recommended. Multilevel EBP incorporating transforaminal administration and fibrin glue should be considered in patients refractory to bilevel EBP. An algorithmic approach to treating SIH is proposed.
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Gerson, James N. , Villa, Diego , Gerrie, Alina S. , Chapani, Parv , Medeiros, L. Jeffrey , Wang, Michael I., Cohen, Jonathon B. , Calzada, Oscar , Churnetski, Michael C. , Hill, Brian T. , Sawalha, Yazeed , Hernandez‐Ilizaliturri, Francisco J. , Kothari, Shalin , Bast, Martin, Fenske, Timothy S. , Gari, Swapna Narayana Rao, Maddocks, Kami J. , Bond, David A. , Bachanová, Veronika , Kolla, Bhaskar , Lansigan, Frederick , Donovan, Alexandra M., Wagner‐Johnston, Nina D. , Messmer, Marcus , Anderson, Jennifer K., Reddy, Nishitha , Kovach, Alexandra E. , Glenn, Martha, Inwards, David J. , Karmali, Reem , Kaplan, Jason , Rajguru, Saurabh, Evens, Andrew M. , Klein, Andreas K. , Umyarova, Elvira , Pulluri, Bhargavi , Amengual, Jennifer E. , Diefenbach, Catherine , Fisher, Richard I., Bachanova, Veronika , Sawalha, Yazeed , Gerrie, Alina S , Evens, Andrew M , Karmali, Reem , Bond, David A , Medeiros, L Jeffrey , Lansigan, Frederick , Diefenbach, Catherine S , Kovach, Alexandra E , Handorf, Elizabeth A. , Li, Shaoying , Vose, Julie M. , Chavez, Julio C , Shah, Bijal , Burns, Timothy Francis , Mehta, Amitkumar , Landsburg, Daniel J. , Caimi, Paolo F. , Lue, Jennifer Kimberly , Barta, Stefan K

Mayo Clinic

Journal of Clinical Oncology | January 7, 2019 | Volume: 37 | Issue: 6 | Pages: 471-480

10.1200/jco.18.00690 | PMID 30615550 Get It

PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score–weighted (PSW) analysis were performed. RESULTS Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
Patient-derived xenografts from breast cancer patients before and after neoadjuvant chemotherapy: A prospective study.
Yu, Jia , Gao, Bowen , Moyer, Ann M. , Visscher, Daniel W., Conners, Amy Lynn , Dockter, Travis , Jones, Katie N., McLaughlin, Sarah A. , Copland, John A. , Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Weinshilboum, Richard M. , Wang, Liewei , Boughey, Judy C. , Yin, Ping , Sinnwell, Jason P. , Kalari, Krishna R. , Suman, Vera J. , Weinshilboum, Richard M. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11130-11130

10.1200/jco.2014.32.15_suppl.11130 Get It

Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens.
Kourelis, Taxiarchis , Dasari, Surendra , Theis, Jason D. , Kurtin, Paul J. , Zeldensrust, Stephen R, Ramı́rez-Alvarado, Marina , Gertz, Morie A. , Doǧan, Ahmet , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8605-8605

10.1200/jco.2014.32.15_suppl.8605 Get It

Utility of restaging bone marrow biopsy (BMB) in PET-negative patients with diffuse large B-cell lymphoma (DLBCL) with bone marrow involvement.
Jackson, Amie E., Smeltzer, Jacob P., Jones, Jason M. , Burnette, Brian L., Ristow, Kay M., Wiseman, Gregory A., Macon, William R. , Nowakowski, Grzegorz S. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8541-8541

10.1200/jco.2014.32.15_suppl.8541 Get It

A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.
Sasaki, Koji , Kelly, Patrick, Kutok, Jeffrey L., Sasaki, Koji , Gotlib, Jason , Mesa, Ruben A. , Ravandi, Farhad , Cortes, Jörge E. , Kantarjian, Hagop M. , Verstovšek, Srđan

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7111-7111

10.1200/jco.2014.32.15_suppl.7111 Get It

Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
Foltz, Lynda, Ritchie, Ellen K. , Silver, Richard T. , Hong, Wan‐Jen , Kremyanskaya, Marina , Trehu, Elizabeth, Verstovšek, Srđan , Mesa, Ruben A. , Gupta, Vikas , Mascarenhas, John , Hoffman, Ronald , Kantarjian, Hagop M. , Gotlib, Jason

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7114-7114

10.1200/jco.2014.32.15_suppl.7114 Get It

Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety
Ritchie, Brianne M., Barreto, Jason N. , Frazee, Erin N. , Crow, Stacy A., Dierkhising, Ross , Jannetto, Paul J. , Tosh, Pritish K. , Dierkhising, Ross A, Razonable, Raymund R.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 3, 2019 | Volume: 63 | Issue: 3 | Pages: No page available

10.1128/aac.01855-18 | PMID 30602515 Get It

The clinical utility of ganciclovir therapeutic drug monitoring (TDM) is unknown. We retrospectively analyzed adult patients treated for cytomegalovirus (CMV) infection with ganciclovir with TDM between 2005 and 2015.